Causes of Mortality After Dose-Escalated Radiation Therapy and Androgen Deprivation for High-Risk Prostate Cancer

被引:16
|
作者
Tendulkar, Rahul D. [1 ]
Hunter, Grant K. [2 ]
Reddy, Chandana A. [1 ]
Stephans, Kevin L. [1 ]
Ciezki, Jay P. [1 ]
Abdel-Wahab, May [1 ]
Stephenson, Andrew J. [3 ]
Klein, Eric A. [3 ]
Mahadevan, Arul [4 ]
Kupelian, Patrick A. [5 ]
机构
[1] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH 44195 USA
[2] Intermt Healthcare, Dept Radiat Oncol, Salt Lake City, UT USA
[3] Cleveland Clin, Dept Urol, Glickman Urol Inst, Cleveland, OH 44195 USA
[4] Seacoast Canc Ctr New Hampshire, Dover, NH USA
[5] Univ Calif Los Angeles Hlth Syst, Los Angeles, CA USA
关键词
RANDOMIZED CONTROLLED-TRIAL; RADIOTHERAPY; SUPPRESSION;
D O I
10.1016/j.ijrobp.2013.05.044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Men with high-risk prostate cancer have other competing causes of mortality; however, current risk stratification schema do not account for comorbidities. We aim to identify the causes of death and factors predictive for mortality in this population. Methods and Materials: A total of 660 patients with high-risk prostate cancer were treated with definitive high-dose external beam radiation therapy (>= 74 Gy) and androgen deprivation (AD) between 1996 and 2009 at a single institution. Cox proportional hazards regression analysis was conducted to determine factors predictive of survival. Results: The median radiation dose was 78 Gy, median duration of AD was 6 months, and median follow-up was 74 months. The 10-year overall survival (OS) was 60.6%. Prostate cancer was the leading single cause of death, with 10-year mortality of 14.1% (95% CI 10.7-17.6), compared with other cancers (8.4%, 95% CI 5.7-11.1), cardiovascular disease (7.3%, 95% CI 4.7-9.9), and all other causes (10.4%, 95% CI 7.2-13.6). On multivariate analysis, older age (HR 1.55, P=.002) and Charlson comorbidity index score (CS) >= 1 (HR 2.20, P<.0001) were significant factors predictive of OS, whereas Gleason score, T stage, prostate-specific antigen, duration of AD, radiation dose, smoking history, and body mass index were not. Men younger than 70 years of age with CS = 0 were more likely to die of prostate cancer than any other cause, whereas older men or those with CS >= 1 more commonly suffered non-prostate cancer death. The cumulative incidences of prostate cancer-specific mortality were similar regardless of age or comorbidities (P=.60). Conclusions: Men with high-risk prostate cancer are more likely to die of causes other than prostate cancer, except for the subgroup of men younger than 70 years of age without comorbidities. Only older age and presence of comorbidities significantly predicted for OS, whereas prostate cancer- and treatment-related factors did not. (C) 2013 Elsevier Inc.
引用
收藏
页码:94 / 99
页数:6
相关论文
共 50 条
  • [1] Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate-and High-Risk Prostate Cancer Reply
    Falchook, Aaron D.
    Basak, Ramsankar
    Chen, Ronald C.
    [J]. JAMA ONCOLOGY, 2017, 3 (02) : 281 - 281
  • [2] PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era
    McGuire, Sean E.
    Lee, Andrew K.
    Cerne, Jasmina Z.
    Munsell, Mark F.
    Levy, Lawrence B.
    Kudchadker, Rajat J.
    Choi, Seungtaek L.
    Nguyen, Quynh N.
    Hoffman, Karen E.
    Pugh, Thomas J.
    Frank, Steven J.
    Corn, Paul G.
    Logothetis, Christopher J.
    Kuban, Deborah A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (01): : E39 - E46
  • [3] CONTINUED BENEFIT TO ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER PATIENTS TREATED WITH DOSE-ESCALATED RADIATION THERAPY ACROSS MULTIPLE DEFINITIONS OF HIGH-RISK DISEASE
    Stenmark, Matthew H.
    Blas, Kevin
    Halverson, Schuyler
    Sandler, Howard M.
    Feng, Felix Y.
    Hamstra, Daniel A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : E335 - E344
  • [4] DOSE-ESCALATED RADIOTHERAPY FOR HIGH-RISK PROSTATE CANCER: OUTCOMES IN MODERN ERA WITH SHORT-TERM ANDROGEN DEPRIVATION THERAPY
    Liauw, Stanley L.
    Stadler, Walter M.
    Correa, David
    Weichselbaum, Ralph R.
    Jani, Ashesh B.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (01): : 125 - 130
  • [5] LACK OF BENEFIT FOR THE ADDITION OF ANDROGEN DEPRIVATION THERAPY TO DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER
    Krauss, Daniel
    Kestin, Larry
    Ye, Hong
    Brabbins, Donald
    Ghilezan, Michel
    Gustafson, Gary
    Vicini, Frank
    Martinez, Alvaro
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1064 - 1071
  • [6] The Addition of Low-dose-rate Brachytherapy and Androgen Deprivation Therapy Decreases Prostate Cancer Death Compared to Dose-escalated External Beam Radiation Therapy for High-risk Prostate Cancer
    Shilkrut, M.
    McLaughlin, W. P.
    Stenmark, M. H.
    Abu-Isa, E.
    Vance, S. M.
    Sandler, H. M.
    Evans, C.
    Feng, F. Y.
    Merrick, G. S.
    Hamstra, D. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S149 - S149
  • [7] Hypofractionated and dose-escalated scanning proton therapy for patients with high risk prostate cancer refusing androgen deprivation
    Herbst, M.
    Walser, M.
    Haidenberger, A.
    Dohr, D.
    Wilms, M.
    Hillbrand, M.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 99 - 99
  • [8] Dose-escalated Radiation Therapy With and Without Short-course Androgen Deprivation for Intermediate-risk Prostate Cancer
    Schreiber, David
    Rineer, Justin
    Surapaneni, Aparna
    Navo, Elliot
    Agarwal, Manuj
    Nwokedi, Emmanuel
    Rotman, Marvin
    Schwartz, David
    [J]. ANTICANCER RESEARCH, 2014, 34 (08) : 4189 - 4193
  • [9] Association of Androgen Deprivation Therapy With Overall Survival in Men With Prostate Cancer Receiving Dose-Escalated Radiation
    Kalbasi, A.
    Li, J.
    Christodouleas, J. P.
    Vapiwala, N.
    Mitra, N.
    Bekelman, J. E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S45 - S45
  • [10] Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate and high risk prostate cancer
    Krauss, D. J.
    Kestin, L. L.
    Brabbins, D. S.
    Gustafson, G. S.
    Chen, P. Y.
    Ghilezan, M. I.
    Vicini, F. A.
    Martinez, A. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S298 - S298